All of those mitigating factors are there and, as I said, we appreciate those and have congratulated the negotiators for having done that. The reality is that there will be extra costs, as I mentioned, with the two-year patent extension. The fact of the matter is generic drug prices have been dropping in Canada as a result of provincial regulation. So the gap between generic prices and brand prices has actually grown.
Generic prices now are capped in many cases somewhere between 18% and 25% of their equivalent brand name product. Any delay does add cost. Again, a very good mitigating factor is these costs for the health care system and these delays for generics will be into the future. So we'll have time to adjust. But if anything, the gap between brand prices and generic prices is going to increase and the costs will therefore increase as well.